Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Debt (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Total Debt data on record, last reported at $286.6 million in Q4 2025.

  • For Q4 2025, Total Debt fell 47.24% year-over-year to $286.6 million; the TTM value through Dec 2025 reached $286.6 million, down 47.24%, while the annual FY2025 figure was $286.6 million, 47.24% down from the prior year.
  • Total Debt reached $286.6 million in Q4 2025 per PTCT's latest filing, roughly flat from $286.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $679.0 million in Q3 2023 and bottomed at $286.3 million in Q3 2025.
  • Average Total Debt over 5 years is $485.0 million, with a median of $495.1 million recorded in 2023.
  • Peak YoY movement for Total Debt: soared 90.27% in 2023, then plummeted 47.24% in 2025.
  • A 5-year view of Total Debt shows it stood at $341.2 million in 2021, then skyrocketed by 88.72% to $643.9 million in 2022, then fell by 25.68% to $478.5 million in 2023, then rose by 13.52% to $543.2 million in 2024, then tumbled by 47.24% to $286.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $286.6 million in Q4 2025, $286.3 million in Q3 2025, and $548.0 million in Q2 2025.